Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach.

Internal medicine journal·2026
Same author

Faith-based Community Engagement in HIV-Testing and Awareness of HIV Status in Southern, Rural, African American Communities.

Journal of racial and ethnic health disparities·2024
Same author

Prevalence, awareness, treatment, and control rates of hypertension in the general population of Australia: a systematic review and meta-analysis.

Journal of hypertension·2024
Same author

Machine learning to predict myocardial injury and death after non-cardiac surgery.

Anaesthesia·2023
Same author

[Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis].

Terapevticheskii arkhiv·2022
Same author

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.

Cardiovascular diabetology·2021
Same journal

Association between retinal microcirculation and cardiac function: A cross-sectional study using OCTA.

Microvascular research·2026
Same journal

Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia.

Microvascular research·2026
Same journal

Association of circulating biomarkers of glycocalyx injury, sirtuin 1, and NFκB p65 in individuals with type 2 diabetes and concurrent arterial hypertension.

Microvascular research·2026
Same journal

Targeting miR-10 alleviates atherosclerosis by enhancing intestinal ABCA1-mediated cholesterol efflux and repairing intestinal barrier.

Microvascular research·2026
Same journal

The effect of acute high-intensity interval exercise on microvascular function and local skeletal muscle oxygenation.

Microvascular research·2026
Same journal

RNF213 deficiency in human iPSC-derived vascular organoids captures key feature of moyamoya disease vasculopathy.

Microvascular research·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Rosuvastatin improves pulse wave reflection by restoring endothelial function.

C Ott1, M P Schneider, M P Schlaich

  • 1Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 Erlangen, Germany.

Microvascular Research
|April 10, 2012
PubMed
Summary
This summary is machine-generated.

Rosuvastatin improved endothelial function in hypercholesterolemic patients by enhancing nitric oxide (NO) bioavailability. This statin therapy reduced vascular stiffness and improved pulse pressure amplification, indicating better vascular health.

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Related Experiment Videos

Last Updated: May 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Endothelial function, indicated by nitric oxide (NO) activity, is crucial for vascular health.
  • Statin therapy may improve vascular function by enhancing NO bioavailability.
  • Hypercholesterolemia is associated with endothelial dysfunction and increased atherosclerosis risk.

Purpose of the Study:

  • To investigate the effects of rosuvastatin on endothelial function and NO bioavailability in hypercholesterolemic patients.
  • To assess whether rosuvastatin improves vascular parameters indicative of endothelial function.

Main Methods:

  • A double-blind, placebo-controlled, crossover study involving 29 hypercholesterolemic patients.
  • Patients received rosuvastatin or placebo for 42 days.
  • Pulse wave analysis, including central augmentation index (cAIx) after N(G)-monomethyl-l-arginine (l-NMMA) infusion, was used to assess NO synthase (NOS) activity and basal NO activity.

Main Results:

  • Rosuvastatin significantly reduced cAIx compared to placebo, indicating improved basal NO activity.
  • Inhibition of NOS by l-NMMA led to a significant increase in cAIx in the rosuvastatin group but not in the placebo group.
  • Pulse pressure amplification (PPA) improved significantly with rosuvastatin treatment.
  • Low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) levels were independent determinants of improved NO activity.

Conclusions:

  • Rosuvastatin treatment improves vascular and endothelial function in hypercholesterolemic patients.
  • Enhanced NO production, influenced by achieved LDL-C and CRP levels, contributes to rosuvastatin's beneficial vascular effects.
  • Rosuvastatin demonstrates a beneficial effect on vascular dysfunction, an early sign of atherosclerosis, in patients without cardiovascular disease.